Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.63 |
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.63 |
| ▸ | CRHBP | P24387 | 1/20 | 0.60 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774835 | 0.91 | HRH4 (0.78) | HRH3HRH4 | |
| SCHEMBL1773938 | 0.85 | HRH4 (0.79) | HRH3HRH4CRHBPCRHR2 | |
| SCHEMBL1774685 | 0.84 | HRH3 (0.55) | HRH3HRH4 | |
| SCHEMBL1775307 | 0.84 | HRH3 (0.55) | HRH3HRH4 | |
| SCHEMBL604610 | 0.83 | HRH4 (0.71) | HRH3HRH4 | |
| SCHEMBL3293436 | 0.83 | CRHBP (0.77) | HRH3HRH4CRHBPCRHR2CYP1A2 | |
| SCHEMBL604406 | 0.81 | HRH4 (0.69) | HRH3HRH4 | |
| SCHEMBL18019805 | 0.78 | NUDT1 (0.74) | HRH4CRHBPCRHR2CYP1A2CYP2D6 | |
| SCHEMBL2166591 | 0.77 | HRH4 (0.73) | HRH3HRH4CRHBPCRHR2CYP1A2 | |
| SCHEMBL1774636 | 0.77 | HRH3 (0.64) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| CN-101341134-B | Pyrimidine derivatives | PFIZER LTD | 2013-05-01 | — | — | CN | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| CN-101341134-A | Pyrimidine derivatives | PFIZER LTD (GB) | 2009-01-07 | — | — | CN | disclosed |
| EP-1966162-A2 | PYRIMIDINE DERIVATIVES | Pfizer Limited (GB) | 2008-09-10 | — | — | EP | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
| WO-2007072163-A2 | PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | HRH3 187/4885HRH4 184/4885CRHBP 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.